Kalydeco (ivacaftor) available at Fairview Specialty Pharmacy
Feb. 15, 2012 - Kalydeco (ivacaftor) has been approved by the FDA and is available at Fairview Specialty Pharmacy.
Kalydeco is approved for the treatment of cystic fibrosis (CF) in patients age 6 years and older who have a G551D mutation in the CFTR gene. This is the first drug that targets the underlying cause of CF for patients with the G551D mutation. It is the result of significant research into the CF gene and possible treatments.
There are only about 1,200 patients in the US who have the CFTR G551D mutation. Fairview Specialty Pharmacy will play an important role to ensure that CF patients who will benefit from Kalydeco will have access to use this new drug. In addition, the pharmacists at Fairview Specialty Pharmacy will help patients safely stay on their Kalydeco, and will work with our payer community to ensure that patients who benefit from Kalydeco will be able to stay on therapy.